The glaucoma book: What do we know now, what do we need to know about glaucoma?

The Glaucoma Book: A Practical, Evidence-Based Approach to Patient Care

Volumn , Issue , 2010, Pages 1015-1021

  Schacknow, Paul N ^a,b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b Visual Health and Surgical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892330859     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-76700-0_92     Document Type: Chapter

References (85)

1. Heinlein RA. Stranger in a Strange Land. New York: Putnam; 1961.
2. Sommer A. Glaucoma risk factors observed in the Baltimore Eye Survey. Curr Opin Ophthalmol. 1996;7(2):93-98.
3. Cioffi GA, Latina MA, Schwartz GF. Argon versus selective laser trabeculoplasty. J Glaucoma. 2004;13(2):174-177.
4. Latina MA, Tumbocon JA. Selective laser trabeculoplasty: a new treatment option for open angle glaucoma. Curr Opin Ophthalmol. 2002;13(2):94-96.
5. Wise JB. Ten year results of laser trabeculoplasty. Does the laser avoid glaucoma surgery or merely defer it? Eye. 1987;1(Pt 1):45-50.
6. Wise JB. Technical considerations in laser trabeculoplasty. Trans New Orleans Acad Ophthalmol. 1985;33:210-214.
7. Eddy DM, Billings J. The quality of medical evidence: implications for quality of care. Health Aff (Millwood). 1988;7(1):19-32.
8. Billings J, Eddy D. Physician decision making limited by medical evidence. Bus Health. 1987;5(1):23. 26-28.
9. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711-1720.
10. Caprioli J, Coleman AL. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123-1129. e1123.
11. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134-142.
12. Bengtsson B, Leske MC, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205-209.
13. Medeiros FA, Weinreb RN, Zangwill LM, et al. Long-term intraocular pressure fluctuations and risk of conversion from ocular hypertension to glaucoma. Ophthalmology. 2008;115(6):934-940.
14. Shuba LM, Doan AP, Maley MK, et al. Diurnal fluctuation and concordance of intraocular pressure in glaucoma suspects and normal tension glaucoma patients. J Glaucoma. 2007;16(3):307-312.
15. Nakakura S, Nomura Y, Ataka S, Shiraki K. Relation between office intraocular pressure and 24-hour intraocular pressure in patients with primary open-angle glaucoma treated with a combination of topical antiglaucoma eye drops. J Glaucoma. 2007;16(2):201-204.
16. Mosaed S, Liu JH, Weinreb RN. Correlation between office and peak nocturnal intraocular pressures in healthy subjects and glaucoma patients. Am J Ophthalmol. 2005;139(2):320-324.
17. Hughes E, Spry P, Diamond J. 24-hour monitoring of intraocular pressure in glaucoma management: a retrospective review. J Glaucoma. 2003;12(3):232-236.
18. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther. 2004;26(1):84-91.
19. Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217-222.
20. Walters TR, DuBiner HB, Carpenter SP, Khan B, Van Denburgh AM. 24-hour IOP control with once-daily bimatoprost, timolol gelforming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49(Suppl 1):S26-S35.
21. Liu JH, Gokhale PA, Loving RT, Kripke DF, Weinreb RN. Laboratory assessment of diurnal and nocturnal ocular perfusion pressures in humans. J Ocul Pharmacol Ther. 2003;19(4):291-297.
22. Liu JH, Kripke DF, Hoffman RE, et al. Nocturnal elevation of intraocular pressure in young adults. Invest Ophthalmol Vis Sci. 1998;39(13):2707-2712.
23. Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol. 2004;138(3):389-395.
24. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713. discussion 829-830.
25. Goldmann H. Un neuveau tonometre. Bull Soc Ophtalmol Fr. 1955;5:281-292.
26. Pekmezci M, Vo B, Lim AK, et al. The characteristics of glaucoma in Japanese Americans. Arch Ophthalmol. 2009;127(2):167-171.
27. Schmidt C. Regulators weigh risks of consumer genetic tests. Nat Biotechnol. 2008;26(2):145-146.
28. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 2001;285(5):540-544.
29. Gerard S, Hayes M, Rothstein MA. On the edge of tomorrow: fitting genomics into public health policy. J Law Med Ethics. 2002;30(3 Suppl):173-176.
30. Rothenberg KH, Terry SF. Human genetics. Before it's too late - addressing fear of genetic information. Science. 2002;297(5579):196-197.
31. Henderer JD. Disc damage likelihood scale. Br J Ophthalmol. 2006;90(4):395-396.
32. Spaeth GL, Henderer J, Liu C, et al. The disc damage likelihood scale: reproducibility of a new method of estimating the amount of optic nerve damage caused by glaucoma. Trans Am Ophthalmol Soc. 2002;100:181-185. discussion 185-186.
33. Smith CM. Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol. 2005;45(4):371-377.
34. Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology. 2009;116(5):823-832.
35. Quigley HA, Addicks EM, Green WR. Optic nerve damage in human glaucoma. III. Quantitative correlation of nerve fiber loss and visual field defect in glaucoma, ischemic neuropathy, papilledema, and toxic neuropathy. Arch Ophthalmol. 1982;100(1):135-146.
36. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99(4):635-649.
37. Quigley HA, Green WR. The histology of human glaucoma cupping and optic nerve damage: clinicopathologic correlation in 21 eyes. Ophthalmology. 1979;86(10):1803-1830.
38. Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol. 2004;138(3):458-467.
39. Boland MV, Quigley HA, Lehmann HP. The impact of risk calculation on treatment recommendations made by glaucoma specialists in cases of ocular hypertension. J Glaucoma. 2008;17(8):631-638.
40. Mansberger SL, Medeiros FA, Gordon M. Diagnostic tools for calculation of glaucoma risk. Surv Ophthalmol. 2008;53(Suppl 1):S11-S16.
41. Gordon MO, Torri V, Miglior S, et al. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114(1):10-19.
42. Mansberger SL, Cioffi GA. The probability of glaucoma from ocular hypertension determined by ophthalmologists in comparison to a risk calculator. J Glaucoma. 2006;15(5):426-431.
43. Mansberger SL. A risk calculator to determine the probability of glaucoma. J Glaucoma. 2004;13(4):345-347.
44. Higginbotham EJ, Richardson TM. Response of exfoliation glaucoma to laser trabeculoplasty. Br J Ophthalmol. 1986;70(11):837-839.
45. Sherwood MB, Svedbergh B. Argon laser trabeculoplasty in exfoliation syndrome. Br J Ophthalmol. 1985;69(12):886-890.
46. Ritch R, Podos S. Laser trabeculoplasty in the exfoliation syndrome. Bull N Y Acad Med. 1983;59(4):339-344.
47. Logan P, Burke E, Joyce PD, Eustace P. Laser trabeculoplasty in the pseudo-exfoliation syndrome. Trans Ophthalmol Soc U K. 1983;103(Pt 6):586-587.
48. Ritch R, Liebmann J, Robin A, et al. Argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmology. 1993;100(6):909-913.
49. Lehto I. Long-term follow up of argon laser trabeculoplasty in pigmentary glaucoma. Ophthalmic Surg. 1992;23(9):614-617.
50. Lunde MW. Argon laser trabeculoplasty in pigmentary dispersion syndrome with glaucoma. Am J Ophthalmol. 1983;96(6):721-725.
51. Robin AL, Pollack IP. Argon laser trabeculoplasty in secondary forms of open-angle glaucoma. Arch Ophthalmol. 1983;101(3):382-384.
52. Sherwood MB, Migdal CS, Hitchings RA, Sharir M, Zimmerman TJ, Schultz JS. Initial treatment of glaucoma: surgery or medications. Surv Ophthalmol. 1993;37(4):293-305.
53. Cairns JE. Trabeculectomy. Preliminary report of a new method. Am J Ophthalmol. 1968;66(4):673-679.
54. Wilkins M, Indar A, Wormald R. Intra-operative mitomycin C for glaucoma surgery. Cochrane Database Syst Rev. 2005;(4): CD002897.
55. Rothman RF, Liebmann JM, Ritch R. Low-dose 5-fluorouracil trabeculectomy as initial surgery in uncomplicated glaucoma: longterm followup. Ophthalmology. 2000;107(6):1184-1190.
56. Hefetz L, Keren T, Naveh N. Early and late postoperative application of 5-fluorouracil following trabeculectomy in refractory glaucoma. Ophthalmic Surg. 1994;25(10):715-719.
57. Stilma JS. Trabeculectomy with 5-fluorouracil in complicated glaucoma. Klin Oczna. 1993;95(2):81-83.
58. Smith MF, Sherwood MB, Doyle JW, Khaw PT. Results of intraoperative 5-fluorouracil supplementation on trabeculectomy for open-angle glaucoma. Am J Ophthalmol. 1992;114(6):737-741.
59. Wilson RP, Steinmann WC. Use of trabeculectomy with postoperative 5-fluorouracil in patients requiring extremely low intraocular pressure levels to limit further glaucoma progression. Ophthalmology. 1991;98(7):1047-1052.
60. Liebmann JM, Ritch R, Marmor M, Nunez J, Wolner B. Initial 5-fluorouracil trabeculectomy in uncomplicated glaucoma. Ophthalmology. 1991;98(7):1036-1041.
61. Taniguchi T, Kitazawa Y, Shimizu U. Long-term results of 5-fluorouracil trabeculectomy for primary open-angle glaucoma. Int Ophthalmol. 1989;13(1-2):145-149.
62. Kitazawa Y, Taniguchi T, Nakano Y, Shirato S, Yamamoto T. 5-Fluorouracil for trabeculectomy in glaucoma. Graefes Arch Clin Exp Ophthalmol. 1987;225(6):403-405.
63. Rauscher FM, Gedde SJ, Schiffman JC, Feuer WJ, Barton K, Lee RK. Motility disturbances in the tube versus trabeculectomy study during the first year of follow-up. Am J Ophthalmol. 2009;147(3):458-466.
64. Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL. Treatment outcomes in the tube versus trabeculectomy study after one year of follow-up. Am J Ophthalmol. 2007;143(1):9-22.
65. Gedde SJ, Herndon LW, Brandt JD, Budenz DL, Feuer WJ, Schiffman JC. Surgical complications in the Tube Versus Trabeculectomy Study during the first year of follow-up. Am J Ophthalmol. 2007;143(1):23-31.
66. Gedde SJ, Schiffman JC, Feuer WJ, Parrish RK 2nd, Heuer DK, Brandt JD. The tube versus trabeculectomy study: design and baseline characteristics of study patients. Am J Ophthalmol. 2005;140(2):275-287.
67. Lewis RA, Von Wolff K, Tetz M, et al. Canaloplasty: circumferential viscodilation and tensioning of Schlemm canal using a flexible microcatheter for the treatment of open-angle glaucoma in adults: two-year interim clinical study results. J Cataract Refract Surg. 2009;35(5):814-824.
68. Grieshaber MC, Pienaar A, Olivier J, Stegmann R. Channelography: imaging of the aqueous outflow pathway with flexible microcatheter and fluorescein in canaloplasty. Klin Monatsbl Augenheilkd. 2009;226(4):245-248.
69. Shingleton B, Tetz M, Korber N. Circumferential viscodilation and tensioning of Schlemm canal (canaloplasty) with temporal clear corneal phacoemulsification cataract surgery for open-angle glaucoma and visually significant cataract: one-year results. J Cataract Refract Surg. 2008;34(3):433-440.
70. Kobayashi H, Kobayashi K, Okinami S. A comparison of the intraocular pressure-lowering effect and safety of viscocanalostomy and trabeculectomy with mitomycin C in bilateral open-angle glaucoma. Graefes Arch Clin Exp Ophthalmol. 2003;241(5):359-366.
71. Shaarawy T, Nguyen C, Schnyder C, Mermoud A. Five year results of viscocanalostomy. Br J Ophthalmol. 2003;87(4):441-445.
72. O'Brart DP, Rowlands E, Islam N, Noury AM. A randomised, prospective study comparing trabeculectomy augmented with antimetabolites with a viscocanalostomy technique for the management of open angle glaucoma uncontrolled by medical therapy. Br J Ophthalmol. 2002;86(7):748-754.
73. Ahmed II, Crandall AS. Viscocanalostomy vs trabeculetomy. Ophthalmology. 2002;109(3):411-412.
74. Jonescu-Cuypers C, Jacobi P, Konen W, Krieglstein G. Primary viscocanalostomy versus trabeculectomy in white patients with openangle glaucoma: a randomized clinical trial. Ophthalmology. 2001;108(2):254-258.
75. Crandall AS. Nonpenetrating filtering procedures: viscocanalostomy and collagen wick. Semin Ophthalmol. 1999;14(3):189-195.
76. Bylsma S. Nonpenetrating deep sclerectomy: collagen implant and viscocanalostomy procedures. Int Ophthalmol Clin. 1999;39(3):103-119.
77. Stegmann R, Pienaar A, Miller D. Viscocanalostomy for open-angle glaucoma in black African patients. J Cataract Refract Surg. 1999;25(3):316-322.
78. Carassa RG, Bettin P, Brancato R. Viscocanalostomy: a pilot study. Acta Ophthalmol Scand Suppl. 1998;227:51-52.
79. Godfrey DG, Fellman RL, Neelakantan A. Canal surgery in adult glaucomas. Curr Opin Ophthalmol. 2009;20(2):116-121.
80. Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma. 2004;13(3):221-226.
81. Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissuespecific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med. 2001;7(3):304-309.
82. Diaz-Aleman VT, Anton A, De La Rosa MG, Johnson ZK, McLeod S, Azuara-Blanco A. Detection of visual-field deterioration by Glaucoma Progression Analysis and Threshold Noiseless Trend programs. Br J Ophthalmol. 2009;93(3):322-328.
83. Robin AL, Clark AF, Covert DW, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147(1):45-50.
84. Minckler D, Baerveldt G, Ramirez MA, et al. Clinical results with the Trabectome, a novel surgical device for treatment of open-angle glaucoma. Trans Am Ophthalmol Soc. 2006;104:40-50.
85. Minckler DS, Baerveldt G, Alfaro MR, Francis BA. Clinical results with the Trabectome for treatment of open-angle glaucoma. Ophthalmology. 2005;112(6):962-967.